吉非替尼联合艾迪治疗老年非小细胞肺癌的临床研究

Clinical Study of Gefitinib Combined with Aidi Injection in Treatment of Non-small-cell Lung Cancer

目的探讨吉非替尼(lressa)联合艾迪注射液治疗老年晚期非小细胞肺癌的有效性和安全性。方法31例经病理学或细胞学确诊的老年晚期非小细胞肺癌患者,接受单药lressa250mg/d或lressa250mg/d联合艾迪注射液治疗,比较其有效性和安全性。结果按照RECIST和WHO标准,31例均可评价疗效和毒性,有效率为22.6%(7/31),疾病控制率为80.6%,中位TTP4个月,以女性和腺癌患者疗效较好。联合组在疾病控制率和症状改善方面均高于单药组,但在统计学上未见显著性差异。结论lressa治疗老年非小细胞肺癌疗效确切,可以明显改善患者的生活质量,而lressa联合艾迪治疗具有更好的倾向,值得进一步探索。

Objective To explore the effects and toxicities of lressa combined with Aidi injection in the treatment of advanced non-small-cell lung cancer(NSCLC).Methods 31 elder patients with histologically or cytologically diagnosed NSCLC were treated with lressa 250mg/d or lressa combined with Aidi injection.Results All the 31 patients might be evaluated.Of the total enrolled patients,the response rate was 22.6%(7/31) and the median time to progression was 4 months.In 25(80.6%) patients,the disease were controlled.There were more benefits in female and adenocarcinoma.The rates of controlled disease and symptoms improvements were higher in the combined group while there were no significant differences between the two groups.Conclusions lressa offers a meaningful tumor and symptoms relief for the patients with NSCLC.The treatment with Chinese traditional medicine Aidi injection is worthy of further research.